Status:
COMPLETED
Daptomycin in the Treatment of Subjects With Infective Endocarditis or Bacteremia Due to S. Aureus
Lead Sponsor:
Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Conditions:
Bacterial Endocarditis
Bacteremia
Eligibility:
All Genders
18+ years
Phase:
PHASE3
Brief Summary
The purpose of this study is to compare the safety and efficacy of daptomycin, an antibiotic, to standard therapy in subjects who have infective endocarditis or bacteremia due to Staphylococcus aureus...
Detailed Description
Even with prompt treatment, Staphylococcus aureus Infective Endocarditis (IE) continues to be associated with significant morbidity and mortality indicating a need for new therapeutic approaches. In v...
Eligibility Criteria
Inclusion
- Documented S. aureus bacteremia within 2 calendar days of the first dose of study medication
Exclusion
- Subjects with a creatinine clearance of less than 30 ml/min
- Subjects with pneumonia
- Pregnant, nursing, or lactating
- Documented history of allergy or intolerance to penicillin or vancomycin
- Subjects with osteomyelitis
Key Trial Info
Start Date :
March 1 2002
Trial Type :
INTERVENTIONAL
End Date :
February 1 2005
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT00093067
Start Date
March 1 2002
End Date
February 1 2005
Last Update
February 13 2017
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.